RBS Australia 19/03/2010 1 Buy $37.50 4.7%
The broker continues to be impressed by the continued strong demand growth for IVIG in Europe and it sees CSL as a key beneficiary given it continues to develop new uses such as a treatment for Alzheimer's.
With no major changes to its forecasts following its latest review the broker retains its Buy rating and $37.50 price target.
credit suisse - $40.50, page-31
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$311.33 |
Change
3.280(1.06%) |
Mkt cap ! $150.4B | |||
| Open | High | Low | Value | Volume |
| $310.00 | $312.47 | $310.00 | $172.6M | 554.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 130 | $311.32 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $311.50 | 210 | 2 |
View Market Depth
| Last trade - 16.10pm 29/07/2024 (20 minute delay) ? |
| CSL (ASX) Chart |